This study enrolls patients with myelodysplastic syndrome (MDS) and myelofibrosis (MFS), with
transfusional iron overload and treats them with the investigational iron chelator, SP-420.
SP-420 may be better tolerated and safer than commercially available iron chelators. Iron
chelation therapy (ICT) has been shown to improve outcomes in iron overload, but adherence is
poor due to problems related to ease of administration, tolerability, and safety.
Clinical Study Identifier
The University of Texas Health Science Center at San Antonio
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.